Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.83 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylitol SCHEMBL13080875 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL4599492 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL5306386 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL8749454 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL5273838 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL20594035 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ribitol SCHEMBL8182152 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL1924966 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL22572531 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL20594034 | 1.00 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113564-A1 | METHODS FOR TREATING CONGENITAL EPIDERMAL HYPERPLASIA AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-04-22 | — | — | US | disclosed |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | LMNA 1527/4885L3MBTL1 3801/4885TDP1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.